Proactive Investors - Run By Investors For Investors

MaxCyte doses first ovarian cancer patient in phase 1 clinical trial

MaxCyte Inc (LON:MXCT) CEO Doug Doerfler sat down with Proactive Investors' Christine Corrado at the Bio Investor Forum in San Francisco.

Over the summer, the US FDA gave the company investigational new drug clearance for MCY-M11, a chimeric antigen receptor that targets solid tumours.

Two weeks ago, the company began dosing its first patient. 

 
Meet MaxCyte, Primary Health Properties PLC, Scancell Holdings PLC and PCF Group Plc at our event, London , 25 April 2019. Register here »
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Video
November 13 2018

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use